Thursday, 14 March 2019

U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)